Similar articles

• Impact factors: target the funding bodies.

  Insall R. Insall R. Nature. 2003 Jun 5;423(6940):585. doi: 10.1038/423585b. Nature. 2003. PMID: 12789312 No abstract available.
• NIH responds to critics on peer review.

  Wadman M. Wadman M. Nature. 2008 Jun 12;453(7197):835. doi: 10.1038/453835a. Nature. 2008. PMID: 18548033 No abstract available.
• Supporting the future.

  [No authors listed] [No authors listed] Nature. 2008 Jun 19;453(7198):958. doi: 10.1038/453958a. Nature. 2008. PMID: 18563096 No abstract available.
• [Research barometer: how is research activity monitored and how is it compared?].

  Djurhuus JC. Djurhuus JC. Ugeskr Laeger. 2003 Jan 20;165(4):322-6. Ugeskr Laeger. 2003. PMID: 12599793 Review. Danish.
• Relationships between sponsors and investigators in pharmacoeconomic and clinical research.

  Schulman KA, Rubenstein LE, Glick HA, Eisenberg JM. Schulman KA, et al. Pharmacoeconomics. 1995 Mar;7(3):206-20. doi: 10.2165/00019053-199507030-00004. Pharmacoeconomics. 1995. PMID: 10155310 Review.